Abstract
Background The accurate estimation of the effective reproductive number (Re) of epidemic outbreaks is of central relevance to public health policy and decision making. We present estimateR, an R package for the estimation of the reproductive number through time from delayed observations of infection events. Such delayed observations may for example be confirmed cases, hospitalizations or deaths. The Re estimation procedure is modularized which allows easy implementation of new alternatives to the already-available methods. Users can tailor their analyses according to their particular use cases by choosing among implemented variations. The package is based on the methodology of Huisman et al. developed as a response to the COVID-19 pandemic.
Results The estimateR R package allows users to estimate the effective reproductive number of an epidemic outbreak based on observed cases, hospitalization, death or any other type of event documenting past infections, in a fast and timely fashion. We validated the implementation with a simulation study, and by comparing results from estimateR to results from the Huisman et al. pipeline on empirical COVID-19 case-confirmation incidence. Compared to existing methods, estimateR implements unique features whose benefit we demonstrated with a simulation study. On simulated data, estimateR yielded estimates of similar, if not better, accuracy than compared alternative publicly available methods while being two to three orders of magnitude faster. In summary, this R package provides a fast and flexible implementation to estimate the effective reproductive number for various diseases and datasets.
Conclusions The estimateR R package is a modular and extendible tool designed for outbreak surveillance and retrospective outbreak investigation. It extends the method developed for COVID-19 by Huisman et al. and makes it available for a variety of pathogens, outbreak scenarios, and observation types. Estimates obtained with estimateR can be interpreted directly or used to inform more complex epidemic models (e.g. for forecasting) on the value of Re.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
TS acknowledges funding from the Swiss National Science foundation (grant number 31CA30 196267).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The estimateR code source, with instructions for the package installation, is available at https://github.com/covid-19-Re/estimateR. The package documentation is available at https://covid-19-re.github.io/estimateR/. Data and scripts to reproduce all analyses and figures presented in the manuscript are available at https://github.com/jscire/estimateR_paper_code.
https://github.com/covid-19-Re/estimateR
Abbreviations
- AR(n)
- autoregressive model of order n;
- COVID-19
- coronavirus disease 2019;
- LOESS
- locally estimated scatterplot smoothing;
- Re
- effective reproductive number
- RMSE
- root mean square error;
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2.
